ClinicalTrials.gg
TerminatedNCT00692614Updated Nov 2, 2015

A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)

A Phase 2 interventional study of triamcinolone acetonide in Macular Edema, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.

Enrollment
24th of 25
2 · median 75
Started
2008
with 1 other
Phase 2
5 of 26
none open now
Registered
8th of 26
by date

Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2008, is one of 5 in phase 2, and was the 8th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing Triamcinolone Acetonide in Macular Edema, or all of them as a file.
02

Study summary

This study will evaluate the treatment effect of three doses of the I-vation TA implant (MK0140) in diabetic patients with clinically significant macular edema.

03

Conditions studied

  • Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has macular edema as a result of their diabetes (Type I or Type 2)
  • Patient has in the study eye, 20/40 - 20/160 vision
  • Patient has Type 1 or Type 2 diabetes
  • Patient agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of

Exclusion criteria

Exclusion Criteria:

  • Patient has had any active ocular infection in either eye
  • Patient has intraocular pressure > 22 mmHg or a diagnosis of glaucoma
  • Patient has cystoid macular edema in the study eye
  • Patient has a history of elevated IOP in response to ocular therapy in either eye
  • Patient has had intraocular surgery in the study eye within 6 months prior to Visit 1
  • Patient has an HbAIc value > 10% at Visit 1
  • Patient has within the last 4 months initiated intensive insulin treatment or plan to do so in the next 4 months
  • Patient has a history of cancer within 5 years prior to signing
  • Patient has clinically-relevant chronic renal failure
  • Patient has high blood pressure
  • Patient has coronary heart disease
  • Patient has known allergies to steroids
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    1

    100 mcg triamcinolone acetonide

    Drug: triamcinolone acetonide

  • Experimental
    2

    500 mcg triamcinolone acetonide

    Drug: triamcinolone acetonide

  • Experimental
    3

    925 mcg triamcinolone acetonide

    Drug: triamcinolone acetonide

  • No intervention
    4

    sham control - not implanted, no medication

Interventions

  • 100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.

    Also known as: MK0140

06

What researchers measure

Primary outcomes

  1. Change from baseline in OCT retinal thickness; evaluate the safety and tolerability of doses.

    Time frame: After 12 months of therapy.

Secondary outcomes

  1. Evaluation of visual acuity; change from baseline in OCT center-point retinal thickness; the need for focal/grid laser photocoagulation during the study; the progression of diabetic retinopathy

    Time frame: After 12 months of therapy.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2008
First posted
Jun 6, 2008
Start
Jun 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
Nov 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00692614
Responsible party
Sponsor
First posted
Jun 6, 2008
Start date
Jun 2008
Primary completion
Nov 2008
Completion
Nov 2008
Last update
Nov 2, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion